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Ambassadors of hope, research pioneers
and agents of change—individuals’
expectations and experiences of taking part
in a randomised trial of an innovative health
technology: longitudinal qualitative study
Julia Lawton1* , Maxine Blackburn1, Jenna P. Breckenridge1,2, Nina Hallowell3, Conor Farrington4 and
David Rankin1
Abstract
Background: While a growing body of research has explored why people take part in clinical trials, this research
has not considered how people’s understandings, motivations and agendas might influence their conduct during a
trial. This is an important area of enquiry because it is now widely recognised that an intervention might lead to
different clinical outcomes when delivered as part of a trial than when implemented in routine clinical practice;
however, the reasons for this are not fully understood.
Methods/design: We interviewed 24 individuals who took part in a trial of an innovative health technology under
development for people with type 1 diabetes which automatically regulates blood glucose: the closed-loop system.
Participants were interviewed following randomisation to a closed-loop and at trial closeout.
Results: Participants provided complex agendas for taking part in which altruistic and self-interested considerations
were often inseparable. Many described belonging to a wider diabetes community and being beneficiaries of
others’ participation in research and how this had given rise to attendant citizenship obligations. Participants also
shared the excitement and pride they experienced from contributing to research which situated them at the
forefront of technological innovation and enabled them to present themselves to others, by virtue of their trial
participation, as ambassadors of hope and research pioneers. Given their desire to support the progression of a
potentially life-changing technology, and be part of that innovation, participants, at follow-up, described having
made extra effort during the trial. Specifically, participants described having been more focused on their diabetes
management to help create conditions in which the closed-loop could work most effectively to optimize their
blood glucose control.
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Conclusions: Our findings contribute a new dimension to understandings of trial effects; specifically, we argue that,
to aid interpretation of trial outcomes, participants’ understandings and motivations for participation need to be
considered. We highlight the potential pertinence of our findings in the contemporary era of bio-citizenship where,
increasingly, people are driving research agendas and see themselves as co-producers of knowledge. We also
recommend a new concept be introduced into the literature—‘the altruselfish agenda’—to recognise potential
inseparability of self-interested and altruistic motivations.
Trial registration: ClinicalTrials.gov, NCT02523131. Registered on 14 August 2015.
Keywords: Trial participation, Trial effects, Diabetes, Qualitative research, Clinical trial, Technology, Medical device
Background
Clinical trials depend on volunteers who might not de-
rive personal health benefit from taking part. Hence, it
has traditionally been assumed that altruism—that is, a
willingness to help others and contribute to the public
good—is a key driver of participation [1]. However, as a
growing body of qualitative research has made apparent,
individuals’ reasons for participating in trials may be
multifaceted. Specifically, individuals tend to present
self-interested agendas alongside altruistic consider-
ations [2–5]. The former might be a hope or expectation
of receiving individualized clinical treatment, despite
trial research being hypothesis rather than needs driven
[1, 5]. People may also choose to take part in trials be-
cause of perceived opportunities for personal therapeutic
benefit arising from ‘incidental’ features of the research,
such as increased monitoring and access to health pro-
fessionals—what has been termed ‘therapeutic appropri-
ation’ [6]. Given that self-interested and altruistic
considerations appear to feature in most individuals’
decision-making, some authors have used caveated ter-
minology to better capture their motivations and
agendas. This includes the concept of ‘weak altruism’
used by Canvin and Jacoby [5] to describe a situation
wherein epilepsy trial participants were “happy to help
others but only where they could also help themselves”
(p10). McCann et al. [1], similarly, used the term ‘condi-
tional altruism’ to describe how the people in their study
were willing to help others with the proviso that trial
participation would also benefit themselves.
The above studies have made an important contribution
to the literature, primarily through offering insights to
help future trial recruitment [1, 2, 4, 5] or by raising and/
or addressing concerns about whether people are making
fully informed decisions about taking part [7–9]. Currently
missing from this literature is consideration of how peo-
ple’s understandings and motivations for taking part might
influence their conduct during a trial. This is an important
area of enquiry because it is now recognised that an inter-
vention may be delivered and received differently within
the context of a trial and, hence, might lead to different
outcomes than when implemented in routine clinical
practice [10, 11]. Indeed, the value of undertaking qualita-
tive (and mixed-methods) research within trials has been
emphasised for this reason [10, 12]. To date, however,
most qualitative studies have focused on staff perspectives
and experiences, as a recent overview of the literature
makes apparent [12]. When trial participants’ perspectives
have been considered, studies have tended to focus on
their likes and dislikes of the intervention [13], mecha-
nisms and mediators of change [14] and reasons for (non)
adherence to the treatments/interventions under investi-
gation [15, 16], without the potential impact of being in a
trial being taken into account.
In this paper, we report findings from a longitudinal
qualitative study undertaken with people who were in-
volved in a randomized controlled trial of a diabetes
technology, currently under development, called a
closed-loop system—which is sometimes also called an
artificial pancreas. This three month trial [17], which in-
volved both adults and young people, built on previous
investigations undertaken by the same team and sought
to test the acceptability and efficacy of the closed-loop
system (as compared to an open-loop system) in the
management of type 1 diabetes, which is a chronic dis-
ease which occurs when the pancreas is unable to pro-
duce insulin. The closed-loop system comprised an
insulin pump, a continuous glucose monitor and a
computer-based algorithm which resided in a separate
handheld device and which translated, in real-time, in-
formation received from the continuous glucose monitor
(which measured interstitial blood glucose every 5–
7 min) in order to compute the amount of insulin deliv-
ered by the pump. Hence, the intended purpose of the
closed-loop was to improve blood glucose control as
well as reducing the burden of diabetes management
[17]. Indeed, in the trial information sheet, potential par-
ticipants were advised that taking part “could help fur-
ther development and refinement of closed-loop systems
that can control blood sugar in people with diabetes.”
A key aim of our interview study was to understand
and explore how people used the closed-loop to support
diabetes management in order to aid interpretation of
trial outcomes and provide recommendations for
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training and support which could be given to future
users to help promote optimal use of the technology [18,
19]. As part of this investigation, we explored people’s
reasons for taking part in the trial as well as their actual
experiences of using the closed-loop system during the
trial. As we describe in this paper, the findings from this
aspect of our study not only prompted us to problem-
atise use of dichotomous categories such as ‘self-interest’
and ‘altruism’, but also to contribute literature on clinical
trials by considering how participants’ understandings of
the trial and their complex and interweaving agendas for
taking part could have profound implications for their
conduct during the trial.
Methods/design
Semi-structured interviews were used as these afforded
flexibility for participants to raise and discuss issues they
perceived as salient, including those unforeseen at the
study’s outset [20]. These interviews were undertaken at
two time-points: just after participants had been ran-
domized to a closed-loop and following their closeout
from the trial 3 months later. Data collection and ana-
lysis took place concurrently, enabling findings from
early interviews to iteratively inform areas explored in
later ones in line with an inductive approach. As detailed
elsewhere [18], the study was informed by Normalization
Process Theory [21], an epistemological position which
recognises that there may be unintended consequences
arising from using a new technology, and that its use
may be influenced by personal and contextual factors
which need to be captured and explored as part of the
data collection and analysis process.
Sample and recruitment
Three groups of individuals were recruited into the inter-
view study by trial staff in the four participating sites in the
United Kingdom (Cambridge, Edinburgh, Manchester and
Leeds) using an opt-in procedure: adult trial participants
(18+ years), adolescent trial participants (13–17 years); and,
parents/caregivers of trial participants aged 13–15 years
and 12 years and under. The decision to interview parents/
caregivers of trial participants aged ≤ 12 years and those
aged 13–15 years was made because, in pre-teenage groups,
parents take overarching responsibility for decision-making
and diabetes management tasks, while sharing these re-
sponsibilities with adolescents. At the time of recruitment
and before commencement of their interviews, it was made
clear to all participants that the interview study was being
conducted by an independent team of experienced qualita-
tive (non-clinical) researchers and that all information
shared would be kept strictly confidential. Recruitment
continued until there was adequate representation of the
different participant groups in the final sample and data
saturation occurred; that is, until no new findings were
identified in new data collected.
MB, an experienced interviewer, conducted the inter-
views at a time and location of participants’ choosing
(mostly in their own homes) using topic guides which
were developed in light of literature reviews, inputs from
parent and patient representatives and members of the
trial’s clinical team, and revised in light of emerging
findings (see above). Key areas explored in the interviews
Table 1 key areas explored in the interviews
Baseline interview
• Background information about study participant, including: who
they live with and what they do (everyday work/school and family
life); details about the child trial participant with type 1 diabetes if the
interviewee is a parent
• Experience of diabetes management prior to the trial, including:
previous regimen used; any challenges and difficulties encountered
undertaking diabetes management tasks and maintaining/achieving
optimal blood glucose control; role and involvement of parents of
child trial participants in undertaking diabetes management tasks
○ Probe to explore: food choices, experiences of counting
carbohydrates, frequency of blood glucose testing, experiences of
determining and administering insulin doses, use of blood glucose
readings, etc.
• Knowledge and understanding of closed-loop technology (e.g. how
the closed-loop works and what it is meant to do, likes and dislikes);
sources of this knowledge
• Previous experiences of taking part in trials/closed-loop research
• Experiences of being recruited into the trial; understandings of the
trial and its purpose; reasons for agreeing to take part (or supporting
child’s decision to take part)
• Reactions to discovering oneself/one’s child had been randomised
to the closed-loop system
• Hopes, expectations and concerns regarding using the closed-loop
during the trial
Follow-up interviews
• Any changes in personal circumstances (e.g. employment, home set
up, lifestyle), since previous interview
• Experiences of using the closed-loop system during the trial, includ-
ing likes and dislikes of using the technology; key challenges encoun-
tered using the closed-loop system; comparisons with previous
regimen; reasons for using/not using the technology in the ways rec-
ommended by trial staff; parents’ views about children operating the
closed-loop system
• Experiences undertaking diabetes management tasks during the trial
○ Probe to explore reasons for any changes in key diabetes self-
management tasks and behaviours since previous interview (e.g.
changes in dietary choices, frequency of and views about blood
glucose testing, reviewing blood glucose data, etc.)
• Participants’ or parents’ level of involvement in managing diabetes
while using the closed-loop system and how this compares with
using previous regimen
○ Probe to explore whether participants’/parents’ focus on diabetes
has changed in any way while taking part in the trial, and why
• Perceptions and understandings of how the closed-loop system
worked and how it affected one’s (or one’s child’s) blood glucose
control
• Views about impact of using the closed-loop system on quality of
life
• Input and support sought and received from staff during the trial;
reasons for contacting staff for support
• Views about how the technology could be improved, and why
• Hopes and expectations regarding the future developments in
closed-loop systems and other diabetes-related technology
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which are relevant to the reporting in this paper are pro-
vided in Table 1.
Interviews took place between July 2016 and August
2017, typically lasted 1–2 h and were digitally recorded
and transcribed in full. Data were analysed by four expe-
rienced qualitative researchers (JL, MB, DR and JPB)
using a thematic approach involving cross-comparison
of all interviews to identify recurrent themes. Each par-
ticipant’s baseline interview was also read in conjunction
with their follow-up interview to identify continuities
and changes in their accounts over time, and compare
expectations with actual experiences of trial participa-
tion. The researchers undertook initial data analyses in-
dependently and wrote separate reports before meeting
to discuss their interpretations and reach agreement on
key themes. A coding frame was then developed which
captured these themes and contextual information
needed to aid data interpretation. Nvivo Version 10
(QSR International Pty Ltd, Doncaster, Victoria,
Australia), a qualitative software package, was used to fa-
cilitate data coding and retrieval and coded datasets
were subjected to further analyses to allow more nu-
anced interpretations of the data to be developed. To
safeguard anonymity, unique (gender neutral) identifiers
are used below.
Results
All participants approached opted-in to the study. See
Table 2 for details of the sample which comprised ten
adult trial participants (aged 18+ years), five adolescent
trial participants (aged 13–17 years) and nine parents.
Below, we begin by reporting participants’ complex
agendas for taking part before considering how these ap-
peared to influence their conduct during the trial. As all
of the main findings cut across the sample, our reporting
has not been separated out according to participant
groups (e.g. adults, adolescents and parents) and
whether individuals had prior experience of taking part
in closed-loop research (Table 2).
Self-interested agendas: therapeutic appropriation and
incidental benefits
For a minority, reasons for taking part in the trial were
driven by self-interested considerations. Such individuals
discussed the personal health benefits they hoped to gain
from having access to continuous glucose monitoring
data (available to individuals in both trial arms) as they
hoped this could be used to help improve their blood
glucose control both during and after the trial, with
some noting that this potential benefit had been pointed
out at the time of recruitment. This included Adult 6
who described how they had:
“hope [d] to improve my diabetic control, for my own
health and benefit … and I’m quite keen on having a
second child, and I was thinking, if I have four
months of [continuous glucose monitoring] data,
that’s properly going to help my control as well.”
Participants’ enthusiasm for taking part in the trial
was also fuelled by the potential opportunity it presented
to use the latest version of the closed-loop. This in-
cluded Adult 3 who highlighted how their own curiosity
had been the main driver: “I’m interested in how it [clo-
sed-loop] works, how quickly the algorithms work and
just the science bit of it.” Adolescent 2, similarly, noted
how the possibility of experiencing closed-loop technol-
ogy first-hand had influenced their decision-making
because:
“closed-loop is like the most exciting thing in the
diabetes world at the moment ... obviously some
people don’t even get the slightest opportunity to try
it, especially not for such a long period of time. So it’s
just sort of like, well yeah, I’m just gonna do it,
because I’ve got this opportunity and it’s really sort of
special.”
Others highlighted additional benefits they hoped to
gain, albeit these were not normally central drivers or
considerations. Adult 8, for instance, described how they
had become a “little bit slapdash” with their diabetes
self-management and had hoped that trial participation,
and regular contact with trial staff, would force them to
“refocus on my diabetes again … I needed this kick up
the backside to do it really.” According to Parent 7, in-
creased contact with clinical staff was also an incentive
for their child’s participation; in this particular case be-
cause of heightened feelings of self-worth arising from
being the centre of trial staff ’s attention:
“He … doesn’t ever feel really special. He obviously
feels very different. So for [child’s name], they made
him feel like an absolute king when he first visited
[names city]. And I think that’s nice for him. And I
think he likes that feeling.”
Altruistic agendas: helping others
A minority, at the other extreme, presented ostensibly
altruistic motivations by stressing that they expected to
gain little or no personal benefit from taking part. This
included Adult 1 who described how:
“I’ve had diabetes for 36 years, I’m more than happy
to help out with these trials for the simple reason that
if people don’t, it’s not gonna progress … and if it all
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works, the technology will progress, it will become
cheaper, so it can be put out on the open market, and
then hopefully youngsters, that kind of technology
would be there for them.”
Indeed, reinforcing their suggestion that altruism had
been their central motivation, Adult 1 also noted how if,
by virtue of randomization, they had not been in the
closed-loop arm of the trial:
“I wouldn’t have had a problem with it, ‘cause they
need the information in order to marry up against the
closed-loop, you know, you can’t just test one side,
you’ve got to go test the other. So, you know, both are
equally valuable.”
While Adult 1 was keen to present themselves as a
“willing volunteer for these kinds of studies” this individ-
ual, like some others, also alluded to a sense of obliga-
tion; albeit, none reported any pressure from staff to
take part. On the contrary, many described how their in-
volvement in diabetes groups and online forums to-
gether with reading articles and diabetes magazines had
generated or reinforced a sense of belonging to “a wider
diabetes community” (Adult 4), one which gave rise to
attendant obligations and responsibilities. As such par-
ticipants noted, access to these groups and information
in the media had not only enabled them to keep up to
date with developments in closed-loop and other dia-
betes technologies, it had also fostered an awareness that
they were beneficiaries of treatments made possible by
others’ participation in earlier diabetes research. This in-
cluded Adult 9, who noted how: “people had to test the
first insulin, people had to test the first pumps, people
had to do this to get to where we’re at now. Somebody’s
always got to take that leap of faith.” A similar observa-
tion was made by Adult 1 who described how “if some-
body didn’t stick up their hand and say ‘yes, I’m willing
to try insulin’, that wouldn’t have progressed.” In making
these kinds of observations, participants, including
Table 2 Demographic characteristics of study participants
Characteristic N % Mean ± SD and range
Adults (n = 10)
Female 5 50.0
Age (years) 39.6 ± 10.6, range 28–65
Occupation
Professional 5 50.0
Semi-skilled 4 40.0
Manual – –
Carer/not working 1 10.0
Previous experience of using a closed loop 3 30.0
Adolescents (n = 5)
Female 2 40.0
Age—all children 15.4 ± 1.5, range 13–17
Education
Secondary school 2 40.0
Higher education 3 60.0
Previous experience of using a closed loop 3 60.0
Parents of child participants (n = 9)*
Female 5 55.6
Age 44.6 ± 5.6, range 35–53
Occupation
Professional 5 55.6
Semi-skilled 2 22.2
Manual 1 11.1
Carer/not working 1 11.1
Previous experience of using a closed loop 3 33.3
*This includes parents who represented children aged ≤ 12 years (n = 5) and parents of adolescents aged 13–15 (n = 4). In one instance, both parents of a child
aged 13–15 years participated in an interview
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Parent 1, also noted the hypocrisy of benefiting from
diabetes treatments without being willing to reciprocate
and contribute to research by putting themselves or
their child forward:
“I think the way that things are moving with the
research and things, I think it’d be sort of hypocritical
to say you know: let other people do this trial. And
then when everything’s done, oh yeah, then we’ll have
one of those please.”
A similar perspective was reported by Adult 4 who
had learned about developments in closed-loop technol-
ogy from a Facebook group, and who discussed how:
“I’m naturally kind of happy to take part in trials
particularly around diabetes, because I get an awful
lot out of the NHS and I think it’s only fair—and if
I’m expecting a cure—I’m gonna want people to have
done this trial.”
Indeed, when asked specifically why they had agreed
to take part, Adult 4 responded:
“There’s my own personal short-term answer which is
I want the [continuous glucose monitoring] data. But
there’s the larger picture of an improved treatment for
the diabetic community. Erm, to be honest it’s on the
future diabetic community probably … there’s always
at the back of my mind, I was four when I became
diabetic, my daughter is now four.”
Hence, even when individuals emphasised ostensibly al-
truistic motivations, most also alluded to self-interested
considerations, whether this be gaining access to data and
support from staff which might help improve their own dia-
betes self-management or, in Adult 4’s case, supporting re-
search which sought to progress a technology from which
they or their own offspring might ultimately benefit.
Interweaving and inseparable agendas: research pioneers
and ambassadors of hope
As the above accounts suggest, while self-interested and
altruistic elements were apparent to varying degrees in
all accounts, in many cases these motivations appeared
to be so inextricably interwoven that they were insepar-
able. This inseparability became particularly apparent
when participants described the excitement they had ex-
perienced, and personal satisfaction they had gained,
from being given the opportunity to be involved in what
they saw as a pioneering study which could be “a proper
game changer” (Adult 6). This included Adolescent 2
and Adult 8, who, like others, suggested that being part
of closed-loop research was much more exciting and
satisfying than learning about developments in the tech-
nology second-hand:
“I thought it was quite exciting. And I just thought:
well this could change future technology for other
people. So I just thought: yeah I’ll be part of that.”
(Adolescent 2)
“you know, you’re always hearing about things which
are in development, which are going to go forward,
but to actually get to the point where, ‘ok, I’m taking
part in a trial’ feels like you’re a bit closer to that and
you can help with that progress, and you’re not just
reading about it in the paper.” (Adult 8)
The excitement arising from taking part in a trial
which could help advance closed-loop technology was
also made only too apparent when Adult 9 shared their
reaction to discovering they had been randomized to the
closed-loop arm:
“I was pretty much useless at work, I was like a child
at Christmas. It is that much of a big deal, it really is
… cause if it works and it goes well, and it becomes a
product which can be supplied to the masses, it’s
gonna absolutely change lives, and I am going to be
part of that.”
Indeed, as many individuals, including Adult 9, noted,
trial participation not only presented an exciting and pri-
vileged opportunity to be directly situated at the fore-
front of technological developments, but also to be part
of research which, ultimately, could change other peo-
ple’s lives. Such an issue became apparent when Adoles-
cent 1’s parents, in a joint interview, reflected upon why
they had supported their child’s decision to take part in
the current and previous closed-loop studies:
(Mum) “I think for him he sees the trials as a positive
part of his diabetes ‘cause it’s kind of hope and
technology and new things. So I think the trial is not
only hope because, for him, it seems very, you know,
like romantic, helping others. But it’s not only that.
For himself he sees it as the exciting part of having
diabetes … (Dad) he has come out saying: ‘how many
people am I helping dad?’ ‘How many do you think
[child’s name]? Millions? There are millions of people
in the world with diabetes [child’s name].’And that’s
made him feel good.”
Connected to their desire to contribute to research
which could help other people, participants described
gaining satisfaction from being able to present themselves
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as research pioneers and ambassadors of hope within their
diabetes networks. A particularly pertinent example was
provided by Adolescent 5, who had already taken part in
several closed-loop studies. While keen to emphasise a
selfless agenda wherein, as they noted, “it’s unlikely I’ll
have one when it first comes out”, Adolescent 5 also re-
lated an anecdote which made apparent that sharing their
experiences of participating in closed-loop research gave
rise to feelings of intense personal gratification and pride:
“I went to a diabetes kind of get-together thing... And
this woman had a young son with diabetes and she was
scared overnight because she thought that he would
have a hypo and possibly die ‘cause he wouldn’t wake
up. And just to think that this stuff [closed-loop
technology] is actually so close that it’ll help so many
people and that you’re a part of that... and you can kind
of be able to tell people who are kind of a bit down, ‘this
is—it’s soon. You’ll—you will have—this technology is
working. You’ll be able to do—that you’ll be able to
have no real worries soon.’ It’s a great experience.”
The satisfaction arising from sharing one’s own or
one’s child’s experiences of contributing to closed-loop
research was equally apparent when, in her interview,
Parent 6 related a separate but similar anecdote:
“And I bumped into a lady when [name’s child] was
on one of them [closed-loop], whose daughter had
only just been diagnosed … And she was saying yeah
‘there isn’t light at the end of the tunnel’, and I said to
her: ‘no no, no, there is light at the end of the tunnel,
you know, you’ve not got to live with the injections
forever and the constant worry when they’re that little
of hypos’ … because they’re doing so much research.
And they’ve got so much funding to do this … so,
yeah, it’s nice to know that in some way we’re helping
bring that day closer.”
Agents of change
While participants thus valued opportunities to be in-
volved in cutting-edge research, many also indicated that
their excitement and motivation for taking part in the
trial had been heightened by their perception that they
could be active agents in the research process. This in-
cluded Adult 7 who described how they had decided to
take part because, “I wanted to be one of the first people
to sort of assist in bringing it to reality in this country”
and Adult 10 who suggested that “that’s why I’m taking
part, hopefully this’ll help these things become a reality
… I hope that in my small way I can—my data will push,
advance the technology forwards.” Indeed, as Adult 10’s
comments make apparent, many participants shared a
perception and understanding that their own (or their
child’s) participation could produce data which could
have a tangible impact on the trial’s outcomes. In some
cases, this perception appeared to have arisen from their
experiences of taking part in, or reading about, previous,
small-scale closed-loop studies and noting, as Adult 1
did, that the technology had evolved in very obvious
ways as a result of this earlier research:
“So the first trial I did was like night-time only … and
there was only 16 of us in that. And the technology
was different and the computer you had was huge as
well in comparison. And as a result of our study they
did the one day one [another trial], a computer and a
mobile phone, and then there is this one, basically a
mobile phone.”
Others, including Adult 6, who described their under-
standing of the trial as being “ultimately to get it li-
censed”, also pointed to what they saw as the relatively
small numbers involved in the current study. As this in-
dividual speculated, this potentially meant that their
own (and others’) data could be very influential: “it’s
quite small numbers of patients, isn’t it. Cause there’s 40
on this trial. Assuming it’s a 50/50 randomization, that’s
only 20 patients to show it works and that it is safe.”
Indeed, with such an awareness and understanding
in mind, another participant, Adult 7, who described
themselves as having “a bit of knowledge around the
area” due to working in a technology-related field,
and saw the current trial as a proof of concept study,
speculated that they might have been approached to
take part because they were particularly well placed
to help evidence the potential efficacy of the closed-
loop system:
“that is why [local PI] pulled on me … with my
knowledge and scientific background I could
potentially help to bring it, to make it into a reality
for more people who don’t have the knowledge or
ability to do this sort of thing.”
Impact of motivations and agendas on the participants’
conduct during the trial
As the above accounts suggest, most participants were
heavily invested in the trial insofar as they really wanted
it to help progress closed-loop technology and also be-
cause of their perception that their own involvement
could help support this process. Indeed, such a goal was
explicitly articulated by Parent 6 who saw their child’s
participation as a way of: “help [ing] them with their
data really, getting as much data as they can … so they
can prove this really helps and then they’ll get more
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funding to do the next stage, so eventually it will be-
come a licensed product.”
As described earlier, follow-up interviews afforded an
opportunity to explore whether participants’ understand-
ings of the trial and their agendas for taking part had
any implications for their trial conduct. In keeping with
their initial agendas, and their understandings that the
technology would need further refinement before being
ready for commercial use, participants described having
put up with a level of inconvenience during the trial
which, they suggested, would have been difficult to sus-
tain in non-trial settings. As well as having had to attend
frequent clinic appointments and upload data for the
trial team on a weekly basis, participants described hav-
ing had to use a prototype device, which was the size of
a large mobile phone, and which they had found heavy
and inconvenient to carry around. Participants also
noted how they had persevered with using this technol-
ogy and had made effort to keep their devices charged
and in close proximity (so that the signal between the
handheld device, the insulin pump and the continuous
glucose monitor was not lost) because of their under-
standing that the trial first needed to “prove that a
closed-loop can be done [developed] and can be done
safely before moving on to the next stage” as Adult 9
suggested, or, as Parent 4 similarly reflected, “it looks
like an old brick, and it weighs about half a kilo but it’s a
prototype and I think they will be more worried about
functionality in the future, once they’ve shown it works.”
In offering the above kinds of reflections which, as re-
ported separately, led to participants offering various
suggestions for how the technology could be improved
for future users [19], participants, in line with their base-
line accounts, also emphasised the bigger picture
wherein they hoped any short-term inconveniences
caused to themselves would be offset by longer-term
benefits to the diabetes community. This included Adult
2 who described encountering particular difficulties
using the technology due to poor eyesight and limited
manual dexterity. As well as disliking, “always having to
carry that big thing around in my handbag”, Adult 2 re-
ported having been frequently disturbed by the technol-
ogy at night because, “it beeped and [because of poor
eyesight] I couldn’t tell if it was charging or not.” Despite
the difficulties they experienced, this individual de-
scribed having talked themselves out of withdrawing
from the trial on the grounds that:
“the closed loop is the way forward, it’s just the
equipment needs to be better … and I felt that I
would let the trial down if I withdrew, because I want
to do anything I can to get diabetics an easier life, and
they needed to have guinea pigs that they can say they
have tested it on, so they could go back and say
closed loop is fantastic and can we have [regulatory]
approval.”
As well as having made effort to use the prototype
system, many participants described having paid
greater attention to their diabetes self-management
during the trial. In a few cases, as participants noted,
this attentiveness had been due to the increased atten-
tion received from trial staff with whom they had had
more frequent contact than in routine clinical care.
Such participants higlighted the heightened sense of
accountability and motivation they had experienced as
a consequence:
“it’s not every day the consultant gives out his mobile
number to a patient is it? You feel like you’re quite an
important patient to them at the time, you know it’s a
lot of investment in one person, I did think they’re
spending quite a significant investment in me and my
diabetes, and I found that really nice and really
motivational.” (Adult 6)
Others noted that they (or their child) had been more
focused on their diabetes self-management due to the
unique and privileged opportunity the trial had afforded
to access cutting-edge technology: “I just felt that I’ve
been given this amazing opportunity to experience
something before everyone else. It made me feel really
special, and that really gave me a real impetus to focus
on my diabetes.” (Adult 9)
In the majority of cases, while participants were
praiseworthy of the system’s ability to automatically
regulate blood glucose because “it is constantly measur-
ing it [blood glucose], and its constantly making adjust-
ments for you” (Adult 1), they also reported having
chosen to work with the closed-loop to optimize their
blood glucose control; for example, by avoiding food-
stuffs which caused sudden rises in blood glucose,
which, as they noted, took time for the closed-loop to
bring down. This included Adult 6, who, in keeping with
their understanding of the trial as being “to prove it
works to get it licensed” and their own desire “to have
helped with that … because this trial will have implica-
tions for when the next generation of the closed-loop
comes out” described how:
“I ate less things that are likely to send your [blood
glucose] high, because I didn’t want to be high, it’s
almost like I wanted it [closed loop] to work if that
makes sense … I was quite fond of the popcorn of an
evening and stuff. And sometimes I’d think: well I
don’t need it. And all it’s gonna do is send me [blood
glucose] up. And then it’ll [closed-loop] have to sort
itself out to come back down. So I just didn’t bother.”
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Adult 8, likewise, described having moderated their al-
cohol consumption during the trial after observing that,
“when you’re drinking over and above two units you can
see the effect on your blood sugar in the morning”.
Adult 8 also described having avoided chocolate and
other sugary snacks “as they cause my blood sugars to
spike” because, as this individual explained, “I assumed
they [trial team] wanted it to show in general that your
HbA1c [glycated haemoglobin—a measure of average
blood glucose control] has come down, and I wanted to
help with that”. A similar kind of motivation and trial
experience was reported by Adolescent 1, who described
how, “I tried to like to keep my HbA1c down through-
out the trial, I tried to control my blood sugars a lot
more, to try to lower my HbA1c” because “I thought the
purpose of the trial was to try and show that it [closed
loop] helps the HbA1c.”
Others, including Adolescent 5, who reported how,
unbeknown to staff, “for a few months I was kind of de-
liberately keeping it [blood glucose] a bit higher so I
could get on the trial, because my blood glucose control
was too good [to meet the trial inclusion criteria],” de-
scribed how they had sought more input and support
from staff than would have happened in a non-trial situ-
ation to help ensure they did not “mess up” the data they
produced for the trial:
“I was more focused on my diabetes during the trial, I
knew what I had to do and the things to kind of stay
away from. Like, for instance, if it’s just your own kit
and stuff, the mistakes you kind of make, you find
shortcuts and things to deal with them. Whereas with
the trial, you don’t want to mess up their data, so you
wanted their input, you know, the ways they wanted
you to deal with it.”
Discussion
As the literature suggests, when people make decisions
about taking part in trials, they weigh up the benefits to
self and the benefits to others [2, 3]. In keeping with this
literature, participants in the current study also pre-
sented both self-interested and altruistic agendas. In
doing so, many of these individuals, who did not neces-
sarily see themselves as future beneficiaries of
closed-loop technology, also described the excitement
that had resulted from taking part in a trial which had
situated them at the forefront of innovation and allowed
them to experience, ahead of others, a cutting-edge tech-
nology first-hand. They also shared the gratification
gained from being able to present themselves to others,
by virtue of their contribution to closed-loop research,
as ambassadors of hope and diabetes research pioneers.
In other words, for this group of individuals, trial
participation could be seen as an intrinsically satisfying
end in itself. Given the interwoven nature of their par-
ticipation agendas, we would argue that even caveated
terminology such as ‘weak’ [5] or ‘conditional’ [1] altru-
ism does not adequately capture the complexity of these
participants’ accounts. Rather, we would argue that a
new concept—‘the altruselfish agenda’—needs to be in-
troduced to recognise the potential blending and insep-
arability of altruistic and self-interested motivations.
Indeed, in much the same way as the philosopher Badh-
war has argued that altruism versus self-interest can be a
false dichotomy because helping others can bolster a
sense of moral self-worth [22], we would argue that con-
tributing to a trial which was seen as ground-breaking
and could potentially change lives was a very self-satisfy-
ing experience.
Underlying their altruselfish agendas, many partici-
pants described belonging to a wider diabetes commu-
nity, one which gave rise to attendant citizenship
responsibilities, including a perceived responsibility to
‘give back’ to the community by taking part in research.
Such a community, as participants’ accounts further
highlighted, transcended geographical and temporal
boundaries, and appeared to have been generated and
reinforced by their access to electronic and other media
[23]. As others have noted, new communication tech-
nologies, such as the world wide web, have given rise to
a new kind of citizenship in the bio-medical era—a form
of digital and informational bio-citizenship, wherein erst-
while disparate individuals have come to self-identify
and align on the basis of shared disease status [24]. As
part of this transformative process, as these authors fur-
ther suggest, bio-citizens no longer see themselves as
passive recipients of health care but, rather, act together
to influence research agendas in the hope of expediting
better treatments for those within their ‘disease’ or ‘bio-
logical’ group [24, 25]. In this study, and in keeping with
the notion of bio-citizenship, participants appeared both
to self-identify with a wider diabetes community which
had attendant citizenship responsibilities and to perceive
themselves as being co-researchers and co-producers of
knowledge who, by virtue of their trial involvement,
could champion and support the progression of
closed-loop technology. By drawing attention to this
bio-citizenship role, our study brings a new and import-
ant question for trial (and potentially other clinical) re-
search to the fore; namely, if individuals do have an
intellectual and personal stake in the research process,
and if they really want an intervention to work, might
this influence how they conduct themselves during a
trial and, hence, potentially its outcomes?
The idea that trial participation can lead to positive
clinical outcomes which may be absent or less apparent
in routine clinical care has already been considered by
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others. Indeed, various researchers have reflected upon
the possibility that trial participation, by its very nature,
might result in improved clinical outcomes independent
of whether the intervention being trialled is more effica-
cious than the control or treatment offered in routine
clinical practice [26]. This phenomenon, which has been
termed the ‘trial effect’ or ‘side effect’ of a trial [27], is
thought to be due to the possibility that, amongst other
things, trial participants may experience a positive care
effect as a result of the extra contact and follow-up sup-
port received from staff [27]. It has also been suggested
that trial participants (and staff ) may change their be-
haviour during a trial because of feeling and/or being
under close observation [26], an issue which has been
termed the ‘Hawthorne effect’ [27, 28]. As the findings
of two key reviews suggest, while the idea of a trial effect
seems plausible, there is currently only weak evidence
for its existence, an issue which, as the authors note,
may be due to difficulties measuring and quantifying this
phenomenon [27, 29]. While these authors highlight
methodological challenges to measuring and determin-
ing trial effects, the absence of studies, such as our own,
drawing directly on trial participants’ own understand-
ings and experiences also needs to be noted.
Our study, with its longitudinal design, allowed us to
explore whether participants’ motivations and agendas
for taking part did, potentially, influence how they con-
ducted themselves during the trial. To this end, and in
keeping with their initial motivations and understand-
ings, participants not only described making effort to
use what was seen as bulky and cumbersome prototype
technology, many also reported being more attentive to,
and focused on, diabetes management by virtue of being
in the trial. As some individuals noted, this extra effort
had been made because they had felt more accountable
to trial staff with whom they had more frequent contact
than in non-trial situations; indeed, some noted that this
desire for increased accountability had influenced their
decisions to take part. While this observation supports
current understandings of a “trial effect”, our analysis
has also drawn attention to how participants’ motiva-
tions for taking part and, relatedly, their intellectual and
emotional investment in progressing closed-loop tech-
nology, also requires consideration. Specifically, and in
line with the altruselfish agendas which had driven their
participation, participants described making effort dur-
ing the trial and having been more focused on their dia-
betes management. As these participants suggested, they
had done this in order to help create the conditions in
which the closed-loop system could work most effect-
ively to optimize their blood glucose control, this being
one of the trial’s primary endpoints.
In line with interview participants’ expectations, un-
derstandings and agendas, the main trial results have
shown that individuals in the closed-loop arm did ex-
perience a significantly greater reduction in HbA1c
levels compared to the control group [30]. While the
clinical efficacy of the technology has thus been demon-
strated in this and a diversity of other trials of
closed-loop systems [31], we have highlighted the im-
portance of considering participants’ own agendas and
agency when interpreting the results of such trials. In
taking our observations and arguments forward, how-
ever, readers may wish to consider that our research in-
volved individuals who did not need the closed-loop to
manage their diabetes and keep themselves alive. In
other words, we might have accessed a very different
kind of trial participant to those in third world countries
and/or who cannot access or afford (private) health care,
amongst whom an altruselfish agenda might not be so
keenly felt [32]. The relatively small-scale nature of the
trial, and some of the closed-loop research which pro-
ceeded it, may also need to be taken into account; spe-
cifically, in terms of how this might have fostered a
perception and understanding that participants’ own ef-
fort and data could potentially have a tangible impact on
the trial’s outcomes. Hence, future work could consider
the perspectives and experiences of those involved in
larger-scale (diabetes) trials, including trials where blind-
ing is possible and, hence, participants do not know
which treatment arm they are in. While we only consid-
ered the perspectives of individuals randomized to the
closed-loop arm, our study raises important questions
about how people might react to being randomized to a
control arm. For instance, do such individuals behave
differently due to disappointment, a competitive element
(and hence, potentially, a desire to beat those in the
intervention arm), or an on-going desire to help prove
the efficacy of a trial intervention by trying less hard?
Only limited insight can be gained from other studies
which have explored the reactions and experiences of
control group participants. Lindström et al. [33], for in-
stance, consulted individuals in the control arms of two
smoking cessation trials. These authors not only found
disappointment to be commonplace but also that, poten-
tially, this led to higher drop-out rates. Petersen et al.
[34] also found disappointment to be the pervading re-
action amongst parents of newborns who were random-
ized to the control group in a trial of the Bacillus
Calmette-Guérin (BCG) vaccine at birth. However, given
this trial only involved a one-off intervention—an injec-
tion which newborns in the control arm did not re-
ceive—it is not possible to determine the implications of
disappointment for subsequent trial conduct.
Conclusions
To date, most work seeking to understand whether, and
why, an intervention might work differently in a trial
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than in routine clinical care has drawn upon the under-
standings and experiences of trial staff. In doing so, this
work has offered important insights into why protocols
and procedures are not always followed in trial contexts
[15, 35–38]. As a complement to this work, our study
highlights the importance of considering trial partici-
pants’ own understandings, motivations and agendas for
taking part. Specifically, our study raises important ques-
tions about how trial results should be interpreted in an
era where, increasingly, patients (bio-citizens) are not
only driving research agendas [24] but may also see
themselves as co-researchers and co-producers of know-
ledge who have an active and personal investment in the
outcomes of (trial) research.
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